

Published by Abbott Investor Relations and Public Affairs  
Investor Newsline: (847) 937-7300

The ticker symbol for Abbott's common shares is ABT. The principal market for Abbott's common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States, Abbott's shares are listed on the London Stock Exchange and the Swiss Stock Exchange.

**On the cover:** *Humira* – Ritsuko Mamiya, Fukuoka, Japan

Ritsuko Mamiya is one of the many patients who take *Humira* to reduce symptoms of moderate to severe rheumatoid arthritis (RA). *Humira* is now approved for three autoimmune disease indications in Japan, including RA, moderate to severe chronic plaque psoriasis and psoriatic arthritis.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Herceptin is not a trademark of Abbott Laboratories.  
The illustration on pages 2-3 is an artist's rendition.

Not all products listed are approved in all countries.

©2010, Abbott Laboratories 120M/4/10



The Abbott 2010 Fact Book was printed with the use of renewable wind power resulting in nearly zero carbon emissions, keeping 2,337.59 pounds of CO<sub>2</sub> from the atmosphere. This amount of wind-generated electricity is equivalent to 2,028 miles not driven in an automobile or 159 trees planted.

Abbott  
100 Abbott Park Road  
Abbott Park, IL 60064-6400 U.S.A.  
(847) 937-6100 www.abbott.com

 **Abbott**  
A Promise for Life

 **Abbott**  
A Promise for Life




Founded in 1888 by Dr. Wallace C. Abbott, a Chicago physician, Abbott is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritional products for children and adults, and medical products, including devices and diagnostic tests and instruments. Headquartered in north suburban Chicago, Abbott employs approximately 83,000 people and markets its products worldwide.

Abbott is focused on advancing patient care by developing innovative solutions in pharmaceuticals, diagnostics, medical devices and nutritional products.

---

2	Financial Highlights	18	Medical Products – Cardiovascular Devices
5	Rankings	19	Medical Products – Medical Optics
6	Pharmaceuticals	19	Medical Products – Animal Health
10	Nutritional Products	20	History
14	Medical Products	23	Global Citizenship
16	Medical Products – Laboratory Diagnostics	26	Five-Year Financial Summary
17	Medical Products – Diabetes Care	28	Plant Locations
17	Medical Products – Molecular Diagnostics	28	Directors
17	Medical Products – Point of Care Diagnostics	29	Senior Management and Corporate Vice Presidents




Pictured:  
Abbott's new *Xience Prime*  
drug-eluting stent

# Financial Highlights

In 2009, Abbott reported sales of \$30.8 billion, with the company's Pharmaceuticals business generating sales of more than \$16 billion, Nutritional Products generating sales of more than \$5 billion, and Medical Products (Medical Devices and Diagnostics) generating sales of more than \$8 billion. In addition, 2009 marked the 37th straight year Abbott's dividend has increased. Abbott has paid 344 consecutive quarterly dividends since 1924.

Abbott's leadership positions in several multi-billion-dollar businesses provide a unique balance of revenue, growth opportunities and cash flow sources that allow us to invest in our future. In 2009, to further strengthen our business and sustain our success, Abbott invested more than \$2.7 billion in research and development.


2009 Sales by Major Operating Segment



- Pharmaceuticals
- Nutritional Products
- Diagnostics
- Medical Devices

Cash Dividends Declared per Share


(dollars per share)



Financial Highlights (continued)

2009 Sales by Geography


(dollars in billions)



- U.S. Sales
- International Sales

5-Year Total Return

(as of December 31, 2009)



Abbott's total return, which accounts for stock price appreciation and dividends, has outperformed the Dow Jones Industrial Average, as well as the S&P 500 and S&P 500 Health Care indices over the last five years.

# Rankings

Abbott is ranked among the top companies in the world for financial strength and workplace excellence by leading national publications, including:

**Barron's** Ranked 24th on *Barron's* "World's Most Respected Companies" list.

**BusinessWeek** Named one of the "Best Places to Launch a Career."

**DiversityInc** Named one of the "Top 10 Companies for Diversity."

**Forbes** Ranked 118th on the *Forbes Global 2000* list (ranked by 2008 sales, profits, assets and market value).

**Fortune** Ranked 1st among the "Most Admired Companies" in the pharmaceutical sector.  
Ranked 80th on the *Fortune 500* list of the largest U.S.-based corporations (ranked by 2008 revenue).

**The Scientist** Named one of the "Best Places to Work in Industry."

**Working Mother** Named one of the "Top 10 Best Employers for Working Mothers."

# Pharmaceuticals

Abbott medicines treat some of the world's most serious and prevalent diseases, including rheumatoid arthritis, Crohn's disease, lipid disorders, kidney disease, prostate cancer, thyroid disease and HIV.

## Virology



## Urology



## Metabolics



## Renal Care



## Cardiovascular



## Immunology



# Pharmaceuticals

Abbott is dedicated to discovering, developing and marketing important treatment options that improve patient health. Abbott sells pharmaceutical products in several therapeutic areas.

**Anesthesia.** Provides inhalation anesthetic agents, neuromuscular blockers, sedatives and other analgesic pain therapies.

*Ultane, Sevofrane (sevoflurane)* Inhalation anesthetic for both inpatient and outpatient procedures, for adult and pediatric use.

**Anti-Infectives.** Antibiotics for the treatment of respiratory infections and skin infections.

*Biaxin, Klacid, Klaricid (clarithromycin), Biaxin XL, Klaricid OD (clarithromycin extended-release formulation)* Oral macrolide antibiotic for the treatment of upper and lower respiratory tract infections. Clarithromycin is also used for skin and skin structure infections, treatment and prevention of Mycobacterium avium complex (MAC) and eradication of the ulcer-causing bacterium H. pylori.

*Erythromycin, PCE* Generic and polymer-coated macrolide antibiotic.

**Cardiovascular.** Includes anti-hypertensive medicines for reducing high blood pressure, treating congestive heart failure and medicines for managing cholesterol abnormalities and triglycerides.

*Biopress, Tiadyf (candesartan)* Angiotensin-2 antagonist for hypertension. (Marketed outside the United States.)

*Niaspan (niacin extended-release tablets), Simcor (niacin extended-release/simvastatin), TriCor (fenofibrate tablets), Trilipix (fenofibric acid) delayed release* Used along with diet and exercise to address lipid abnormalities.

*Simdax (levosimendan)* Injectable for acute congestive heart failure. (Marketed in Latin America only.)

**Gastroenterology.** Medications used to treat disorders and conditions associated with the gastrointestinal tract.

*Duphalac (lactulose)* Prebiotic that stimulates the growth and activity of beneficial bacteria of the intestinal flora.

**Hormonal Health.** Oral and topical hormonal treatments.

*AndroGel (testosterone gel)* Testosterone gel to treat men with a deficiency or absence of testosterone.

**Immunology.** Medication used to treat some diseases of the immune system.

*Humira (adalimumab)* Self-injectable, TNF-blocking, recombinant monoclonal antibody for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe Crohn's disease, moderate to severe chronic plaque psoriasis and moderate to severe polyarticular juvenile idiopathic arthritis.

**Metabolics.** Includes medicines for the management of obesity and the treatment of thyroid disease.

*Synthroid (levothyroxine sodium)* Synthetic thyroid hormone for the treatment of hypothyroidism and subclinical hypothyroidism.

**Neuroscience and Pain Care.** Medications to treat neurological conditions.

*Depakote ER (divalproex sodium, extended-release tablets), Depakote, Epival, Valcote (divalproex sodium enteric-coated tablets)* Anti-epileptic agent (adult/pediatric) also used for the treatment of the manic episodes of bipolar disorder (adult) and for the prevention of migraine headaches (adult).

*Duodopa (levodopa/carbidopa)* Treatment system for advanced Parkinson's disease. (Marketed outside the United States)

*Serc (betahistine dihydrochloride)* Used for the treatment of Ménière's disease and vestibular vertigo.

**Pancreatic Enzymes.** Medications used for the treatment of pancreatic exocrine insufficiency.

*Creon (pancrelipase)* Pancreatic enzyme used for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

**Pediatric and Neonatal.** Medications for newborns and pediatric patients with serious respiratory conditions.

*Survanta (beractant)* Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

*Synagis (palivizumab)* Monoclonal antibody for the prevention of serious lower-tract respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV. (Marketed outside the United States.)

**Renal Care.** Includes oral and injectable activated vitamin D agents developed to treat patients with complications of chronic kidney disease.

*Zemplar (paricalcitol injection and capsules)* Therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.

**Urology and Reproductive Health.** Includes medicines for the palliative treatment of advanced prostate cancer, endometriosis, anemia associated with uterine fibroids and central precocious puberty.

*Lupron Depot, Lucrin (leuprolide acetate depot suspension)* Synthetic hormone for the treatment of advanced prostate cancer, endometriosis, preoperative treatment of anemia associated with uterine fibroid tumors in combination with iron and central precocious puberty.

**Vaccines.** Used to protect against the influenza virus.

*Influvac* Influenza vaccine.

**Virology.** Medications to treat HIV.

*Kaletra, Aluvia (lopinavir/ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

*Norvir (ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

# Nutritional Products

Abbott offers some of the world's most trusted brands in pediatric nutrition, therapeutic nutrition and performance nutrition. We also provide specially formulated medical nutrition products for patients with unique dietary needs due to illness or injury.



Performance Nutrition

Pediatric Nutrition

Therapeutic Nutrition



## Nutritional Products

Abbott is a leader in providing trusted pediatric and adult nutrition formulas, shakes, bars, snacks and tube-feeding products to improve people's quality of life.

**Pediatric Nutrition.** Abbott develops products that support the growth and development of infants and children and makes these products available in innovative, consumer-friendly packaging. Specialty formulations include products for premature and low-birth-weight infants and products for infants and children with special tolerance or nutritional needs.

<i>Gain Advance</i>	A nutritional supplement for children 6 months to 1 year old during the transition to solid foods. <i>Gain Advance</i> contains the <i>Eye-Q</i> system of nutrients, nucleotides and increased levels of protein and energy to support brain development, the immune system and overall growth. (Marketed outside the United States.)
<i>Gain Plus Advance</i>	Nutritional choice for children 1 to 3 years old. The <i>Eye-Q</i> system is also available with <i>Gain Plus Advance</i> , and it contains pre- and probiotics (synbiotics) to help support children's natural defenses. (Marketed outside the United States.)
<i>Gain Kid, Gain School</i>	Growth-focused nutritional supplements for children 3 years old and beyond, delivering more than 30 essential nutrients. <i>Gain Kid</i> is also available with the <i>Eye-Q</i> system of nutrients. (Marketed outside the United States.)
<i>PediaLyte</i>	Oral electrolyte maintenance solution to help prevent dehydration by quickly replacing fluids and electrolytes lost during diarrhea and vomiting. Also available as <i>PediaLyte Powder Packs</i> , <i>PediaLyte Freezer Pops</i> and <i>PediaLyte Singles</i> .
<i>PediaSure and PediaSure Complete</i>	Complete, balanced nutritional formula in a variety of flavors for children 1 to 13 years old. Available with fiber, as an oral supplement and in a tube-feeding formulation. <i>PediaSure Complete</i> (marketed outside the United States) contains synbiotics.
<i>Similac</i>	A full line of milk and soy based complete infant and toddler nutrition products that support healthy development of a baby's immune system, brain, eyes, and bones. The line also includes highly specialized products to meet the unique needs of premature and low-birth-weight babies, including <i>Similac Human Milk Fortifier</i> , <i>Similac Special Care</i> and <i>Similac Expert Care NeoSure</i> .
<i>Similac Advance</i>	Milk-based infant formula that provides complete nutrition for baby's first year. Has the unique benefits of <i>EarlyShield</i> for immune support, brain and eyes, and strong bones. Includes a patented blend of immune-supporting nucleotides, and prebiotics and carotenoids, DHA/ARA for brain and eye development and is the only leading formula with no palm olein oil for strong bones.
<i>Similac Advance Organic</i>	The first major brand-name organic infant formula that is certified USDA Organic and has the trusted nutritional benefits of <i>Similac</i> baby formula with the wholesomeness of organic milk.
<i>Similac Expert Care Alimentum</i>	A formula for infants with food allergies or colic due to protein sensitivity.
<i>Similac Expert Care NeoSure</i>	A special nutrient-enriched, iron-fortified formula for babies born prematurely. It is clinically shown to support excellent catch-up growth.
<i>Similac Sensitive</i>	Milk-based infant formula for mild gastrointestinal intolerance symptoms such as fussiness and gas. Now has <i>EarlyShield</i> .
<i>Similac Sensitive For Spit Up</i>	Milk-based formula with added rice starch. Clinically shown to reduce the frequency of spit-up by 54 percent.
<i>Similac Sensitive Isomil Soy</i>	The number-one formula for complete soy nutrition — can help reduce fussiness and gas in infants and toddlers. Now has <i>EarlyShield</i> .

**Performance Nutrition.** Abbott offers a broad selection of nutrition bars, shakes and related products that satisfy a wide range of consumer nutrition needs.

<i>EAS</i>	A leading brand of specialized sports nutrition bars, shakes and dietary supplements designed to help athletes and fitness enthusiasts meet their fitness, performance and endurance goals.
<i>ZonePerfect</i>	A leading brand of nutrition bars that provide convenient, all-natural nutrition for busy people.
<b>Therapeutic Nutrition.</b>	Abbott offers medical nutritionals and devices for patients with special dietary needs who require tube feeding or other nutritional interventions due to complex illness or injury. Abbott also offers specialized nutrition products for infants and children with multiple food allergies, severe gastrointestinal impairment or metabolic diseases.
<i>Companion, EnteraLite Infinity, Patrol, Quantum</i>	Complete line of enteral feeding pumps, tubes and devices.
<i>EleCare</i>	Nutritional formula for infants and children with multiple food allergies or severe gastrointestinal impairment.
<i>Ensure</i>	A broad line of leading adult nutritional products, providing a source of complete, balanced nutrition to help people get well and stay well. <i>Ensure</i> shakes are available in a variety of flavors and nutritional formulations.
<i>Glucerna, Glucerna SR</i>	The first therapeutic nutritional product for people with diabetes or patients with impaired glucose tolerance. Available in shakes, meal bars, cereal, snack bars and tube-feeding formulations. <i>Glucerna SR</i> (marketed outside the United States) is an advanced formulation to improve glycemic control and help people with diabetes achieve or maintain optimal weight management.
<i>Jevity</i>	Fiber-fortified liquid formula line available with various protein and caloric levels for both short- and long-term tube feeding.
<i>Juven, Abound</i>	Therapeutic nutrition drink mix to help patients and support wound healing.
<i>Nepro, Suplena</i>	Specialized nutritional products for people with kidney disease.
<i>Oxepa, Pulmocare</i>	Specialized nutritional products for patients with respiratory conditions, including acute lung injury/acute respiratory distress syndrome ( <i>Oxepa</i> ) and pulmonary disease ( <i>Pulmocare</i> ).
<i>ProSure</i>	A clinically tested therapeutic nutritional product, specially designed to help people with cancer-induced weight loss gain weight and strength and improve their quality of life. (Marketed outside the United States.)
<i>Vital Jr.</i>	Specialized nutrition for children with malabsorption, maldigestion and other GI conditions to help them maintain normal growth and development.

# Medical Products

Abbott drives innovation in the fast-paced medical technology market. Our medical products are advancing disease diagnosis, vision care, diabetes management and the treatment of vascular disease.



Diabetes Care



Diagnostics



Medical Optics

Cardiovascular Devices



## Medical Products – Laboratory Diagnostics

Abbott Laboratory Diagnostics offers a broad range of innovative instruments and tests across key segments in the global diagnostics market, including hospitals, reference laboratories, blood banks, physician offices and clinics.

**Immunoassay and Clinical Chemistry.** Includes systems and assays to measure a variety of analytes found in the blood and to diagnose and monitor diseases and therapies. Also includes blood-screening instrumentation and assays used to ensure the safety of the blood supply.

<a href="#">AbbottLink</a>	Software that transmits instrument performance information to Abbott's service operations through the Internet, enhancing the remote identification and rapid resolution of technical issues on select analyzers.
<a href="#">ABBOTT PRISM</a>	Fully automated analyzer specifically designed for high-volume blood and plasma centers and blood banks to screen donated blood and plasma for multiple viral assays. Menu includes Chagas disease, HIV, hepatitis and HTLV assays. (Not all assays are available in the United States.)
<a href="#">ACCELERATOR Automated Processing Systems</a>	Automates the labor-intensive sample identification, routing, centrifugation and storage logistics in the laboratory. <i>ACCELERATOR APS</i> improves process consistency, reduces dependency on manual labor and enhances overall operator safety.
<a href="#">ARCHITECT ci4100</a>	Clinical chemistry analyzer that performs diagnostic tests to monitor general health including a patient's levels of sodium, potassium, chloride and organ function. The <i>ci4100</i> is an automated analyzer that completes both immunoassay and chemistry tests on one platform.
<a href="#">ARCHITECT c8000, c16000, c4000</a>	Low-, medium- and high-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty chemistry testing.
<a href="#">ARCHITECT ci8200, ci16200</a>	Analyzers that integrate the <i>ARCHITECT</i> clinical chemistry analyzers and the <i>i2000SR</i> instrument to provide a consolidated workstation to perform both clinical chemistry and immunoassay testing.
<a href="#">ARCHITECT i4000SR, i2000SR, i1000SR</a>	Modular analyzers that provide immunoassay testing. Menu includes tests for cancer, infectious disease, cardiovascular and thyroid disease, fertility and pregnancy.
<a href="#">AxSYM Plus</a>	Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular and thyroid disease, drugs of abuse, fertility, hepatitis, pregnancy and infectious disease.
<a href="#">IMx</a>	Automated benchtop analyzer for immunoassay testing. Menu includes tests for cardiovascular and thyroid disease, cancer and fertility.
<a href="#">Instrument Manager</a>	Software that provides connectivity and functionality across the entire laboratory, reducing turnaround time and labor dependency, while improving the quality of results.
<a href="#">TDx, TDx Fix</a>	Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline, vancomycin, drugs of abuse and thyroid tests.

**Hematology.** Abbott develops, manufactures and markets *CELL-DYN* hematology systems used to perform sophisticated blood cell analysis.

<a href="#">CELL-DYN Ruby, 3700, 3200</a>	Complete line of highly automated hematology analyzers to meet the testing needs of any laboratory, whether high or low volume.
<a href="#">CELL-DYN Emerald, 1800</a>	Low-volume, automated hematology analyzer for small to midsize clinical laboratories.
<a href="#">CELL-DYN Sapphire</a>	High-volume, automated hematology analyzer that incorporates monoclonal antibody tests, reducing the need for external sample analysis.

## Medical Products – Diabetes Care

Abbott Diabetes Care is committed to improving the lives of people with diabetes by providing innovative glucose monitoring systems that offer patients and health care professionals fast, convenient and accurate results.

<a href="#">FreeStyle Freedom Lite blood glucose monitoring system</a>	Easy-to-hold, easy-to-read blood glucose monitoring system that uses a 0.3 microliter blood sample, has the most approved alternative sites for testing, features a 5-second average test time and requires no coding.
<a href="#">FreeStyle Lite blood glucose monitoring system</a>	Small, discreet blood glucose monitoring system that offers key features such as no coding and the world's smallest blood sample size.
<a href="#">Precision Xceed Pro</a>	A hand-held, point-of-care blood glucose monitoring system used in the hospital.
<a href="#">Precision Xtra advanced diabetes monitoring system</a>	The only home-use meter capable of measuring both blood glucose and blood ketone levels. ( <i>Optium</i> outside the United States.)

## Medical Products – Molecular Diagnostics

Abbott Molecular offers innovative tests and instruments for early detection of pathogens and genomic and chromosomal changes, allowing for earlier diagnosis, selection of appropriate therapies and disease monitoring.

<a href="#">Abbott m2000 and Abbott RealTime tests for HIV-1, HBV, HCV, HCV Genotyping, HPV, CT/NG, CT and mS9</a>	Automated system integrates sample preparation and extraction with real-time polymerase chain reaction (PCR) amplification and detection technology. Menu includes tests for human immunodeficiency virus (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), HCV Genotyping, human papillomavirus (HPV), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), CT, and methylated septin 9 for colorectal cancer (mS9). (Not all tests are available in the United States.)
<a href="#">Cystic Fibrosis Genotyping Assay</a>	Qualitative <i>in vitro</i> diagnostic device used to genotype a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator gene in genomic DNA isolated from human whole blood specimens.
<a href="#">Fluorescence in-situ Hybridization (FISH) Probe Technology</a>	Genomic DNA tests for chromosomal changes associated with congenital disorders and cancer.
<a href="#">PlexID Biosensor system</a>	Next-generation <i>Ibis T-5000</i> System designed for rapid identification of bacteria, viruses, and fungi and to provide information about strain type, virulence, and drug resistance. Intended for research use only.
<a href="#">PathVysion HER-2 DNA Probe Kit</a>	Detects the HER-2/neu gene in breast cancer patients. Patients who have extra copies of this gene are candidates for treatment with Herceptin, a targeted monoclonal antibody treatment.
<a href="#">UroVysion Bladder Cancer Kit</a>	DNA-based test for the initial diagnosis of patients suspected of having bladder cancer presenting with hematuria (blood in urine), and the monitoring of cancer recurrence in patients diagnosed with bladder cancer.
<a href="#">ViroSeq HIV-1</a>	Genotyping system used as an aid in monitoring and treating HIV infection. Detects HIV-1 mutations associated with drug resistance.

## Medical Products – Point of Care Diagnostics

Abbott Point of Care Diagnostics develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis.

<a href="#">i-STAT System</a>	An advanced, handheld diagnostic tool that provides real time lab-quality results within minutes to accelerate patient-care decision making. The <i>i-STAT</i> System has the industry's most comprehensive menu of tests in a single platform including tests for blood gases, electrolytes, chemistries, coagulation, hematology, glucose, and cardiac markers.
-------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Medical Products – Cardiovascular Devices

Abbott Vascular Devices markets a broad portfolio of coronary, endovascular, vessel closure and structural heart technologies used in the treatment of cardiac and vascular care.

### Coronary

<i>HI-TORQUE</i> guide wires	Full array of coronary guide wires that assist clinicians in accessing lesions, navigating tortuous anatomy, treating chronically stenosed lesions, and supporting the delivery of bulky devices.
<i>MULTI-LINK VISION, MULTI-LINK MINI VISION</i> stents	Thin-strut metallic coronary stents based on cobalt chromium technology. <i>MULTI-LINK MINI VISION</i> is for use in small vessels (2.0 mm to 2.5 mm), and <i>MULTI-LINK VISION</i> is for use in vessels 2.75 mm to 4.0 mm.
<i>MULTI-LINK 8</i>	Next-generation, bare-metal stent with an enhanced delivery system designed for greater flexibility and deliverability. (Approved in CE Mark countries only)
<i>VOYAGER</i> balloons	Line of coronary balloons enabling access to difficult lesions and the potential for superb stent expansion in the arteries surrounding the heart. Includes <i>VOYAGER NC</i> , a high-pressure balloon dilatation catheter for use in both pre-dilatation and post-dilatation procedures.
<i>XIENCE V</i>	Drug-eluting coronary stent developed on the <i>MULTI-LINK VISION</i> platform. The <i>XIENCE V</i> stent combines the cobalt chromium stent with everolimus to treat coronary lesions in patients with coronary artery disease.
<i>XIENCE PRIME</i>	A next-generation drug-eluting stent with a novel stent design and modified delivery system designed for greater flexibility and enhanced deliverability. (Approved in CE Mark countries only. Currently in development in the United States.)

### Endovascular

<i>Acculink, AccUNET</i>	The <i>Acculink</i> carotid stent is a conformable, self-expanding nitinol stent designed for use in the carotid arteries of the neck that carry blood to the brain. It is used with the <i>AccUNET</i> embolic protection system, a filter to capture plaque fragments (emboli) that may be dislodged during carotid stenting procedures.
<i>Fox Balloons (FoxCross, Fox Plus and Fox sv)</i>	Line of peripheral balloons for endovascular procedures designed for optimal crossing and deliverability of small and large vessels.
<i>Xact, Emboshield NAV<sup>6</sup></i>	<i>Xact</i> is a self-expanding stent designed for use in the carotid arteries of the neck that carry blood to the brain. <i>Emboshield NAV<sup>6</sup></i> is a filter used to capture plaque fragments (emboli) that may be dislodged during carotid stenting procedures.

### Structural Heart

<i>MitraClip</i>	A catheter-based system designed to reduce mitral regurgitation by adapting the open surgical double-orifice technique in a less invasive procedure. (Approved in CE Mark countries only. Currently in development in the United States.)
------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Vessel Closure

<i>Perclose ProGlide, Perclose ProStar</i>	Suture-mediated vessel closure devices designed to expedite recovery following diagnostic or interventional catheterization procedures.
<i>StarClose SE</i>	Vascular closure device that features a flexible nitinol clip to enable secure extravascular closure of the femoral artery access site in diagnostic or interventional catheterization procedures.

## Medical Products – Medical Optics

Abbott Medical Optics provides market-leading technologies to address a wide range of vision disorders.

### Cataract Products

<i>Healon Viscoelastics</i>	Protective gel that is injected into the eye for enhanced stability and control during surgery.
<i>ReZoom Multifocal IOL</i>	Refractive intraocular lens (IOL) that uses optical zones to provide near, intermediate and distance vision, reducing the need for eyeglasses.
<i>Synchrony Accommodating IOL</i>	A next-generation accommodating IOL designed to mimic the eye's natural ability to change focus and deliver improved vision at all distances for patients following cataract surgery. (Currently in development in the United States.)
<i>Tecnis IOL</i>	Implant used in cataract surgery to replace the natural lens with one that improves vision at a single focal point.
<i>Tecnis Multifocal IOL</i>	Implant used in cataract surgery to replace the natural lens with one intended to provide near, intermediate and distance vision with reduced dependence on eyeglasses or contact lenses.
<i>WhiteStar Signature Phacoemulsification System</i>	Ultrasonic device that emulsifies and extracts a hard, cloudy lens (cataract) and makes it easier to remove through a small incision.

### Corneal Products

<i>Blink Contacts Lubricating Eye Drops</i>	Revitalizes and soothes the dry eyes of contact lens wearers.
<i>Blink Tears Lubricating Eye Drops</i>	Mimics the natural elements of tear film and provides other benefits that alleviate the symptoms of dry eyes.
<i>COMPLETE Multi-Purpose Solution Easy Rub Formula</i>	Single-bottle solution formulated to effectively clean and disinfect contact lenses.
<i>Oxysept UltraCare Formula: Peroxide Disinfection System</i>	Hydrogen peroxide system that provides powerful disinfection efficacy for contact lenses.

### Refractive Products

<i>Advanced CustomVue Procedure</i>	<i>LASIK</i> procedure that corrects unique imperfections in each patient's eyes and is capable of treating the industry's broadest range of refractive conditions.
<i>IFS Advanced Femtosecond Laser</i>	Ultrafast laser that focuses pulses of light below the surface of the cornea to create the corneal flap before a <i>LASIK</i> treatment is performed.
<i>STAR S4 IR Excimer Laser System</i>	Computer-driven ultraviolet laser that corrects refractive errors by reshaping the cornea during <i>LASIK</i> procedures.
<i>WaveScan WaveFront System</i>	Measures imperfections and produces a detailed map of the eye, which is digitally transferred to the excimer laser, providing high levels of precision and accuracy.

## Medical Products – Animal Health

Abbott Animal Health is a leader in perioperative health care for the veterinary market. Products include anesthetic and wound-care products, nutritionals, a complete line of IV fluid therapy and other veterinary critical-care products.

<i>AlphaTRAK blood glucose monitoring system</i>	Blood glucose monitoring system calibrated and validated for dogs, cats, horses, ferrets, mice and rats that provides accurate results within seconds.
<i>Fluid Therapy</i>	Complete line of IV fluids, sets, catheters and accessories that provide venous access, keep organs properly perfused and help maintain blood pressure.
<i>GLUture Topical Tissue Adhesive</i>	Medical-grade adhesive indicated for wound closure.
<i>SevoFlo (sevoflurane)</i>	Inhalant anesthetic that provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.

## A tradition of innovation.

For more than 120 years, Abbott has been a pioneer in developing innovative solutions that improve health and the practice of health care. In 1888, 30-year-old Wallace C. Abbott, M.D., began making a new form of medicine. Using the active – or alkaloid – part of a medicinal plant, he formed tiny pills, called “dosimetric granules,” which provided a measured amount of the drug. The demand for these accurate granules soon far exceeded the needs of his own practice. From a small operation based above Dr. Abbott’s pharmacy, Abbott has evolved into one of the world’s leading health care companies.

1888	Dr. Abbott begins producing dosimetric granules in his apartment on Chicago’s North Side.
1900	The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.
1915	The company changes its name to Abbott Laboratories.
1920	Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Ill.
1929	Abbott stock is listed on the Chicago Stock Exchange. The offering is 20,000 shares for \$32 each.
1931	Abbott establishes its first international affiliate in Montreal, Canada. The company’s international presence will grow steadily.
1936	Abbott introduces the anesthetic agent Pentothal, developed by Abbott scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they are named to the U.S. Inventors Hall of Fame in 1986.
1941	Abbott is one of the five pioneers in the United States to start commercial production of penicillin.
1952	Erythrocin, a new antibiotic with good activity against grampositive bacteria, is introduced.
1962	Abbott enters a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals. Major plant expansions are completed in England, Italy and France.
1964	The company acquires M&R Dietetic Laboratories of Columbus, Ohio, which eventually becomes Abbott Nutriron.
1965	Abbott moves major operations to Abbott Park, a 420-acre site southwest of its North Chicago headquarters.

1973	Abbott forms its diagnostics division to bring together all diagnostic products and services. The company also introduces <i>Ensure</i> , its first adult medical nutritional.
1977	TAP Pharmaceuticals is formed as a joint venture between Abbott and Takeda Chemical Industries, Ltd., of Japan.
1983	<i>Depakote</i> , a new treatment for epilepsy, is approved in the United States.
1985	Abbott wins U.S. approval to market the world’s first diagnostic test for HIV/AIDS. TAP receives approval for <i>Lupron</i> , a new therapy for prostate cancer.
1987	<i>Hytrin</i> , a new cardiovascular drug for the treatment of hypertension, receives U.S. Food and Drug Administration (FDA) approval.
1988	Abbott celebrates its centennial. The <i>IMx</i> immunoassay system is introduced and goes on to become one of the best-selling new products in Abbott’s history.
1990	<i>Biaxin</i> , an important new macrolide antibiotic, is introduced.
1991	Several major products are launched worldwide, including <i>Survanta</i> , for the treatment of neonatal respiratory distress syndrome. Abbott enters the hematology testing market with the acquisition of Sequoia-Turner Corp.
1993	<i>Hytrin</i> receives FDA clearance for use in treating symptoms of benign prostatic hyperplasia, a condition of the prostate. Abbott launches <i>AxSYM</i> , a new, labor-saving diagnostic system.
1994	Abbott introduces sevoflurane, the first truly universal anesthetic, and completes an agreement to cross-license LCR and PCR, two gene amplification technologies.
1995	TAP receives approval for <i>Prevacid</i> , a proton pump inhibitor used in treating ulcers. <i>ABBOTT PRISM</i> , the first fully automated, high-volume blood analyzer, is introduced outside the United States.
1996	The company receives FDA approval for <i>Norvir</i> , a protease inhibitor for the treatment of HIV and AIDS. The company enters the glucose testing market with its acquisition of MediSense, Inc.
1997	Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc., and also launches several new products, including an improved version of <i>Similac</i> infant formula in the United States.
1998	Abbott launches <i>Glucerna</i> shakes and snack bars, specially formulated nutritionals for people with diabetes. <i>Depakote</i> surpasses lithium as the most-prescribed drug for treating mania. Abbott launches several pharmaceutical products, including <i>Zemplar</i> , <i>TriCor</i> and <i>Synagis</i> .
1999	Abbott launches <i>ARCHITECT</i> , a next-generation diagnostic system, and acquires Perclose, Inc., a leading vascular closure devices company.

- 2000** Abbott receives FDA approval for several new drugs or new formulations, including *Kaletra* (an advanced-generation protease inhibitor for the treatment of HIV/AIDS), *Biaxin XL* (a once-daily version of its flagship antibiotic) and *Depakote ER* (for migraine prevention).
- 2001** Abbott completes the acquisition of the pharmaceutical business of BASF, including the global operations of Knoll Pharmaceuticals. In addition, Abbott acquires Vysis, Inc., a leading genomic disease management company.
- 2002** Abbott receives FDA approval for *Humira* (for moderate to severe rheumatoid arthritis) and *Synthroid* (for hypothyroidism). The company launches *Similac Advance*, *Isomil Advance* and *NeoSure Advance* infant formulas in the United States. Abbott acquires the cardiovascular stent business of Biocompatibles International plc.
- 2003** Abbott launches three new immunodiagnosics systems on the *ARCHITECT* platform. Abbott receives European regulatory approval for *Humira* to treat rheumatoid arthritis. Abbott acquires JOMED's coronary and peripheral intervention business lines, ZonePerfect Nutritional Co. and Integrated Vascular Systems Inc.
- 2004** Abbott acquires TheraSense Inc., a leading blood glucose monitoring business, as well as i-STAT Corp. and EAS Inc. Abbott creates Hospira, an independent, publicly traded company. Hospira is one of the largest global specialty pharmaceutical and medication delivery companies serving the hospital market.
- 2005** Abbott introduces several medical devices, including the *Xact/Emboshield* carotid stent system, *StarClose* vascular closure device and, in the United States, diagnostic devices *ABBOTT PRISM* and *CELL-DYN Sapphire*. Abbott also receives FDA approval for two new indications for *Humira* (psoriatic arthritis and early rheumatoid arthritis).
- 2006** Abbott acquires the vascular business of Guidant Inc., a leader in coronary and vascular products, and Kos Pharmaceuticals, a specialty pharmaceutical company with a significant cholesterol management portfolio. Abbott also launches its *XIENCE V* drug-eluting stent outside the United States.
- 2007** Abbott submits a record number of major products for regulatory approval and launches *Humira* for moderate to severe Crohn's disease and *Niaspan* to treat cholesterol and triglycerides.
- 2008** Abbott receives nine major regulatory approvals, including three indications for *Humira*, *Simcor*, *ARCHITECT i1000sr*, *FreeStyle Navigator* continuous glucose monitoring system, *FreeStyle Freedom Lite*, *XIENCE V* and *Trilipix*. Abbott also concludes its TAP joint venture.
- 2009** Abbott acquires Advanced Medical Optics (AMO), Evalve, Visiogen and Ibis Biosciences. Also, Abbott receives approval for *XIENCE V* in China and Canada, and CE Mark for *XIENCE PRIME*.
- 2010** Abbott acquires Solvay Pharmaceuticals and STARLIMS. Abbott also receives approval for *XIENCE V* in Japan.

# Global Citizenship

We view our commitment to global citizenship as an opportunity to improve lives around the world.

Good corporate citizenship is at the core of our business strategy to develop, manufacture and market innovative products that answer critical health needs. It is reflected in how we expand access to health care, strengthen local communities and reduce the environmental impact of our operations.

Our efforts have earned Abbott inclusion in the Dow Jones Sustainability Index — the leading global benchmark of best-in-class economic, environmental and social performance — for five consecutive years.

As a leader in citizenship, we must continuously reassess our responsibilities and opportunities to improve people's lives. In 2009, Abbott continued to make progress in advancing citizenship in four key areas.



## Global Citizenship (continued)

### Innovating for the future

In 2009, Abbott renewed its focus on its primary citizenship responsibility: advancing medical innovation to transform people's health around the world. We strengthened our commitment to addressing unmet health needs by establishing an executive council on neglected diseases to apply the expertise of our scientists to help advance new treatments for diseases like malaria and tuberculosis. We also partnered with the Drugs for Neglected Diseases initiative (DNDi) to identify existing molecular compounds in Abbott's research library that may offer promise in addressing neglected diseases.

### Improving access

A primary focus for our business is ensuring that people in need have access to our health care products. We work with governments in less developed and middle-income countries to make our medicines available at fair, sustainable prices. Additionally, in 2009, Abbott and the Abbott Fund invested more than \$580 million in capacity-building partnerships, product donations and patient assistance programs.

### Protecting patients and consumers

Our approach is to ensure quality and safety across the full spectrum of research, development, manufacturing and use of our products. To help protect and inform patients, we have launched educational websites in many countries, providing treatment and disease-related information, responding to questions and connecting patients with each other.

### Safeguarding the environment

Abbott also is helping to address the global challenges of climate change and water scarcity. During 2009, we reduced carbon dioxide emissions in our manufacturing operations by 5 percent from our 2008 levels through an ongoing energy efficiency improvement program. By increasing our energy efficiency and using cleaner fuels, Abbott reduced its use of oil and coal by 35 percent in recent years. Abbott also is saving a billion gallons of water annually by reducing water use throughout our production processes.

These are just a few examples of how Abbott is redefining responsibility across our diverse mix of businesses and geographies. By strengthening the sustainability of our day-to-day operations and using our expertise to advance global health care, we are working to meet the needs of both current and future stakeholders.

For a copy of our full Global Citizenship Report, please visit [www.abbott.com/citizenship](http://www.abbott.com/citizenship).

This child in Vietnam's Linh Thuong District, Quang Tri, is among hundreds of those receiving healthy nutrition support from a partnership between the Abbott Fund, Giao Diem and AmeriCares to address the country's high prevalence of pediatric malnutrition.

# Five-Year Financial Summary

(dollars in millions, except per share data)

Year Ended December 31	2009	2008	2007	2006	2005
Summary of Operations:					
Net sales	\$30,764.7	29,527.6	25,914.2	22,476.3	22,337.8
Cost of products sold	\$13,209.3	12,612.0	11,422.0	9,815.1	10,641.1
Research and development (a)	\$ 2,743.7	2,688.1	2,505.6	2,255.3	1,821.2
Selling, general and administrative	\$ 8,405.9	8,435.6	7,408.0	6,349.7	5,496.1
Operating earnings	\$ 6,235.7	5,693.8	4,578.5	2,042.2	4,362.3
Interest expense	\$ 519.7	528.5	593.1	416.2	241.4
Interest income	\$ (137.8)	(201.2)	(136.8)	(123.8)	(87.7)
Other (income), net	\$ (1,375.5)	(489.7)	(347.5)	(526.5)	(411.3)
Earnings from continuing operations before taxes	\$ 7,193.8	5,856.3	4,469.6	2,276.4	4,619.9
Taxes on earnings from continuing operations	\$ 1,447.9	1,122.1	863.3	559.6	1,247.9
Earnings from continuing operations	\$ 5,745.8	4,734.2	3,606.3	1,716.8	3,372.1
Basic earnings per share from continuing operations	\$ 3.71	3.06	2.34	1.12	2.17
Diluted earnings per share from continuing operations	\$ 3.69	3.03	2.31	1.12	2.16
Financial Position:					
Working capital	\$10,264.4	5,106.8	4,939.5	(669.3)	3,970.5
Long-term investments	\$ 1,132.9	1,073.7	1,125.3	1,229.9	134.0
Net property and equipment	\$ 7,619.5	7,219.2	7,518.1	6,946.4	6,003.1
Total assets	\$52,416.6	42,419.2	39,713.9	36,178.2	29,141.2
Long-term debt	\$11,266.3	8,713.3	9,487.8	7,009.7	4,571.5
Shareholders' investment	\$22,898.7	17,518.7	17,823.9	14,054.2	14,415.3
Return on shareholders' investment from continuing operations	% 28.4	26.9	22.7	12.1	23.5
Book value per share	\$ 14.76	11.26	11.47	9.14	9.37
Other Statistics:					
Gross profit margin	% 57.1	57.3	55.9	56.3	52.4
Research and development to net sales	% 8.9	9.1	9.7	10.0	8.2
Net cash from operating activities of continuing operations	\$ 7,275.2	6,994.6	5,183.8	5,262.1	5,047.4
Capital expenditures	\$ 1,089.0	1,287.7	1,656.2	1,337.8	1,207.5
Cash dividends declared per common share	\$ 1.60	1.44	1.30	1.18	1.10
Common shares outstanding (in thousands)	1,551,168	1,552,433	1,549,910	1,537,243	1,539,235
Number of common shareholders	67,461	69,733	73,176	77,727	82,237
Number of employees	72,868	68,838	68,697	66,663	59,735
Sales per employee (in dollars)	\$ 422,198	428,943	377,225	337,163	373,948
Market price per share – high	\$ 57.39	61.09	59.50	49.87	50.00
Market price per share – low	\$ 41.27	45.75	48.75	39.18	37.50
Market price per share – close	\$ 53.99	53.37	56.15	48.71	39.43

(a) In 2009 and 2006 Abbott also recorded pretax charges of \$170 and \$2,014, respectively, for acquired in-process research and development related to business acquisitions.

## Plant Locations

Abbott's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400. The locations of Abbott's principal plants, as of December 31, 2009, are listed below.

Abbott Park, Illinois	Katsuyama, Japan
Alameda, California*	Longford, Ireland
Altavista, Virginia	Ludwigshafen, Germany
Anasco, Puerto Rico*	Milpitas, California*
Barceloneta, Puerto Rico	North Chicago, Illinois
Brockville, Canada	Ottawa, Ontario, Canada*
Buenos Aires, Argentina	Redwood City, California*
Campoverde di Aprilia, Italy	Rio de Janeiro, Brazil
Casa Grande, Arizona	Santa Clara, California
Clonmel, Ireland	Singapore
Columbus, Ohio	Sligo, Ireland
Cootehill, Ireland	Sturgis, Michigan
Dartford, England*	Temecula, California
Des Plaines, Illinois	Tlalpan, Mexico
Fairfield, California*	Wiesbaden, Delkenheim, Germany
Granada, Spain	Witney, Oxon, England
Irving, Texas	Worcester, Massachusetts
Jayuya, Puerto Rico	Zwolle, the Netherlands
Karachi, Pakistan	

\*Leased property

## Directors

Robert J. Alpern, M.D.  
*Dean, Yale School of Medicine  
New Haven, Conn.*

Roxanne S. Austin  
*President and  
Chief Executive Officer  
Move Networks, Inc.  
American Fork, Utah  
and President,  
Austin Investment Advisors  
Newport Coast, Calif.*

William M. Daley  
*Vice Chairman and  
Head of the Office of  
Corporate Responsibility  
and Chairman of the Midwest,  
JPMorgan Chase & Co.  
Chicago, Ill.*

W. James Farrell  
*Retired Chairman and  
Chief Executive Officer,  
Illinois Tool Works, Inc.  
Glenview, Ill.*

H. Laurance Fuller  
*Retired Co-Chairman  
of the Board,  
BP Amoco, p.l.c.  
London, United Kingdom*

William A. Osborn  
*Retired Chairman and  
Chief Executive Officer,  
Northern Trust Corporation  
and The Northern Trust Co.  
Chicago, Ill.*

The Rt. Hon. Lord Owen, CH  
*Chairman of Europe Steel, Ltd.  
London, United Kingdom*

Roy S. Roberts  
*Managing Director,  
Reliant Equity Investors  
Chicago, Ill.*

Samuel C. Scott III  
*Retired Chairman, President  
and Chief Executive Officer,  
Corn Products International, Inc.  
Westchester, Ill.*

William D. Smithburg  
*Retired Chairman, President  
and Chief Executive Officer,  
The Quaker Oats Co.  
Chicago, Ill.*

Glenn F. Tilton  
*Chairman, President and  
Chief Executive Officer,  
UAL Corporation and United Air Lines,  
Inc., a wholly owned  
subsidiary of UAL Corporation  
Chicago, Ill.*

Miles D. White  
*Chairman of the Board  
and Chief Executive Officer,  
Abbott*

## Senior Management

Miles D. White\*  
*Chairman of the Board  
and Chief Executive Officer*

Thomas C. Freyman\*  
*Executive Vice President,  
Finance and Chief  
Financial Officer*

Richard W. Ashley\*  
*Executive Vice President,  
Corporate Development*

Olivier Bohuon\*  
*Executive Vice President,  
Pharmaceutical Products*

John M. Capek, Ph.D.\*  
*Executive Vice President,  
Medical Devices*

Holger A. Liepmann\*  
*Executive Vice President,  
Nutritional Products*

Edward L. Michael\*  
*Executive Vice President,  
Diagnostic Products*

Laura J. Schumacher\*  
*Executive Vice President,  
General Counsel and  
Secretary*

Carlos Alban\*  
*Senior Vice President,  
International  
Pharmaceuticals*

Thomas F. Chen\*  
*Senior Vice President,  
International Nutrition*

Stephen R. Fussell\*  
*Senior Vice President,  
Human Resources*

Robert B. Hance\*  
*Senior Vice President,  
Vascular*

John C. Landgraf\*  
*Senior Vice President,  
Pharmaceuticals,  
Manufacturing and Supply*

John M. Leonard, M.D.  
*Senior Vice President,  
Pharmaceuticals,  
Research and Development*

Heather L. Mason\*  
*Senior Vice President,  
Diabetes Care*

James V. Mazzo\*  
*Senior Vice President,  
Abbott Medical Optics*

Donald V. Patton, Jr.\*  
*Senior Vice President,  
U.S. Pharmaceuticals*

Mary T. Szela\*  
*Senior Vice President,  
Global Strategic  
Marketing and Services,  
Pharmaceutical Products  
Group*

Michael J. Warmuth\*  
*Senior Vice President,  
Diagnostics*

J. Scott White\*  
*Senior Vice President,  
U.S. Nutrition*

## Corporate Vice Presidents

Greg E. Arnsdorff  
*Vice President,  
Point of Care Diagnostics*

Michael G. Beatrice, Ph.D.  
*Vice President,  
Corporate Regulatory and  
Quality Science*

Brian J. Blaser  
*Vice President,  
Diagnostics, Operations*

William J. Chase  
*Vice President, Licensing  
and Acquisitions*

Jaime Contreras  
*Vice President,  
International Diagnostics*

Thomas J. Dee  
*Vice President, Contoller,  
Pharmaceutical Products*

Charles D. Foltz  
*Vice President,  
Vascular Products  
Operations*

Robert B. Ford  
*Vice President,  
Diabetes Care,  
Commercial Operations*

Robert E. Funck  
*Vice President, Chief Ethics  
and Compliance Officer*

John F. Ginascol  
*Vice President,  
Nutrition, Supply Chain*

Honey Lynn Goldberg  
*Vice President,  
Associate General  
Counsel, Corporate  
Transactions*

Thomas A. Hurwich  
*Vice President,  
Internal Audit*

Cecilia L. Kimberlin, Ph.D.  
*Vice President, Quality,  
Medical Products*

Zahir A. Lavji  
*Vice President,  
Pharmaceuticals,  
International Marketing*

Elaine R. Leavenworth  
*Vice President,  
Government Affairs*

Steven J. Lichter  
*Vice President,  
Pharmaceuticals,  
Manufacturing*

Greg W. Linder\*  
*Vice President, Contoller*

Santiago Luque  
*Vice President,  
Pharmaceuticals,  
Latin America*

Corlis D. Murray  
*Vice President,  
Corporate Engineering  
Services*

D. Stafford O'Kelly  
*Vice President,  
Molecular Diagnostics*

Ramachandran  
Rajamanickam  
*Vice President, Nutrition,  
Pacific, Asia and Africa*

Pascale Richetta  
*Vice President,  
Pharmaceuticals, Western  
Europe and Canada*

John R. Schilling, M.D.  
*Vice President,  
Sales and Marketing,  
U.S. Pharmaceutical  
Operations*

AJ J. Shoultz  
*Vice President, Taxes*

Preston T. Simons  
*Vice President,  
Information Technology*

James P. Sullivan, Ph.D.  
*Vice President,  
Pharmaceuticals Discovery*

Eugene Sun, M.D.  
*Vice President,  
Pharmaceuticals  
Clinical Development*

John B. Thomas  
*Vice President,  
Investor Relations and  
Public Affairs*

Glenn S. Warner  
*Vice President,  
Solvay Commercial  
Integration*

Susan M. Widner  
*Vice President,  
Corporate Marketing*

Gary M. Winer  
*Vice President,  
Pharmaceuticals,  
Japan*

Valentine Yien  
*Vice President, Treasurer*

\*Denotes executive officer